Grace Therapeutics GRCE
NASDAQ GRCE
$1.91 -0.06 (-2.79%)
At close: Oct 22, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Price to Sales (2022 - 2026)

Updated

Grace Therapeutics' (GRCE) Price to Sales stood at 229.33 in fiscal Q4 2022 (quarter ended Mar 31, 2022).

Analysis

Grace Therapeutics (GRCE) Price to Sales (2022 - 2026) Analysis & Trends

For FY2021 (ended Mar 31, 2021), Grace Therapeutics' Price to Sales came in at 363.15.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Grace Therapeutics 32.47 Mn -33.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 59.30
Mar 31, 2026 108.15
Dec 31, 2025 73.14
Sep 30, 2025 61.29
Jun 30, 2025 58.93
Mar 31, 2025 42.96
Dec 31, 2024 69.71
Sep 30, 2024 72.95
Jun 30, 2024 84.60
Mar 31, 2022 229.33
API Access

Grace Therapeutics Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=GRCE&period=max&api_key=YOUR_API_KEY